{"log_id": 6491455400058060422, "direction": 0, "words_result_num": 30, "words_result": [{"probability": {"variance": 0.001912, "average": 0.989539, "min": 0.711994}, "location": {"width": 795, "top": 272, "height": 29, "left": 240}, "words": "每天给药1250mg剂量C稳态几何平均值为2.43μg/mL(95%可信区间1.57"}, {"probability": {"variance": 0.016007, "average": 0.953049, "min": 0.391143}, "location": {"width": 579, "top": 321, "height": 27, "left": 199}, "words": "3.77g/mL),AUC值为36.2Mg*h/mL(23.4-56g*h/mL)"}, {"probability": {"variance": 5.8e-05, "average": 0.996062, "min": 0.962696}, "location": {"width": 821, "top": 384, "height": 32, "left": 240}, "words": "本品与食物同时服用后全身暴露量增加。本品与低脂饮食(5%脂肪[500卡路里]"}, {"probability": {"variance": 0.007922, "average": 0.977375, "min": 0.44359}, "location": {"width": 862, "top": 429, "height": 34, "left": 200}, "words": "或高脂饮食(50%脂肪[1,000卡路里])同时服用则其AUC值大约分别增高3或4倍"}, {"probability": {"variance": 0.017358, "average": 0.960244, "min": 0.485399}, "location": {"width": 261, "top": 479, "height": 28, "left": 202}, "words": "(Cm大约升高2.5或3倍)"}, {"probability": {"variance": 0, "average": 0.999454, "min": 0.998912}, "location": {"width": 50, "top": 546, "height": 27, "left": 200}, "words": "分布"}, {"probability": {"variance": 0.003759, "average": 0.985178, "min": 0.622941}, "location": {"width": 837, "top": 607, "height": 32, "left": 241}, "words": "本品能与白蛋白和a-1酸性糖蛋白高度结合(超过99%)。体外研究显示本品是乳"}, {"probability": {"variance": 0.00409, "average": 0.982141, "min": 0.578993}, "location": {"width": 869, "top": 653, "height": 31, "left": 200}, "words": "腺癌耐药蛋白BCRP(ABCG2)和p一糖蛋白的底物(ABCB1)。体外研究也显示本品在临"}, {"probability": {"variance": 0.020551, "average": 0.950397, "min": 0.35281}, "location": {"width": 877, "top": 699, "height": 31, "left": 199}, "words": "床有效浓度时能抑制Pgp(IC2.3μg/mL),BCRP(IC0.014μg/mL)和肝脏摄取转运"}, {"probability": {"variance": 0.001548, "average": 0.984398, "min": 0.781435}, "location": {"width": 874, "top": 743, "height": 35, "left": 203}, "words": "蛋白OATP1B1(IC2.3g/ml)。这些作用对其他药物药代动力学的影响或其他抗癌药物"}, {"probability": {"variance": 0.000395, "average": 0.994467, "min": 0.87757}, "location": {"width": 870, "top": 790, "height": 30, "left": 201}, "words": "的药理学影响的临床意义还不清楚。本品不会明显抑制肾转运蛋白OAT和OCT(体外实"}, {"probability": {"variance": 0.013176, "average": 0.956795, "min": 0.54371}, "location": {"width": 268, "top": 840, "height": 26, "left": 202}, "words": "验显示(ICs值≥6.9g/ml)"}, {"probability": {"variance": 0.049342, "average": 0.683441, "min": 0.461309}, "location": {"width": 105, "top": 813, "height": 47, "left": 798}, "words": "产国"}, {"probability": {"variance": 0, "average": 0.999267, "min": 0.998666}, "location": {"width": 47, "top": 904, "height": 26, "left": 203}, "words": "代谢"}, {"probability": {"variance": 2.2e-05, "average": 0.997429, "min": 0.981231}, "location": {"width": 802, "top": 965, "height": 29, "left": 243}, "words": "本品体内代谢有多种酶的参与,主要经过CYP3A4和CYP3A5代谢,少部分经由"}, {"probability": {"variance": 1.5e-05, "average": 0.997934, "min": 0.978018}, "location": {"width": 850, "top": 1011, "height": 28, "left": 201}, "words": "CYP2C19和CYP2C8代谢,产生多种氧化代谢产物,但均不超过粪便中重吸收药物的"}, {"probability": {"variance": 7e-06, "average": 0.998826, "min": 0.988667}, "location": {"width": 309, "top": 1059, "height": 26, "left": 202}, "words": "14%,或血浆中本品浓度的10%"}, {"probability": {"variance": 0.004778, "average": 0.98225, "min": 0.560721}, "location": {"width": 816, "top": 1123, "height": 28, "left": 241}, "words": "在临床有效浓度下,本品在体外能抑制CYP3A(Ki0.6-2.3g/mL)和CYP2C8"}, {"probability": {"variance": 0.000379, "average": 0.990799, "min": 0.896268}, "location": {"width": 802, "top": 1169, "height": 28, "left": 212}, "words": "0.3μg/mL)。本品不能明显抑制下述的人体肝微粒体中的酶:CYP1A2,CYP2C9"}, {"probability": {"variance": 0.00124, "average": 0.985314, "min": 0.804197}, "location": {"width": 608, "top": 1214, "height": 27, "left": 201}, "words": "CYP2C19,和CYP2D6或UGT酶(体外IC3值≥6.9g/mL)"}, {"probability": {"variance": 0.018447, "average": 0.846739, "min": 0.710921}, "location": {"width": 153, "top": 1219, "height": 47, "left": 891}, "words": " GUANGDONG PHARE"}, {"probability": {"variance": 2e-06, "average": 0.988208, "min": 0.98688}, "location": {"width": 155, "top": 1249, "height": 56, "left": 841}, "words": "华润"}, {"probability": {"variance": 0, "average": 0.955332, "min": 0.955332}, "location": {"width": 33, "top": 1265, "height": 35, "left": 996}, "words": "东"}, {"probability": {"variance": 0.017583, "average": 0.956878, "min": 0.409096}, "location": {"width": 804, "top": 1272, "height": 69, "left": 242}, "words": "健康志愿者接受CYP3A4抑制剂酮康唑,每天2次,每次2医药有限公司"}, {"probability": {"variance": 7e-06, "average": 0.998215, "min": 0.987811}, "location": {"width": 513, "top": 1325, "height": 28, "left": 202}, "words": "的全身暴露量能够提高3.6倍,半衰期延长1.7倍"}, {"probability": {"variance": 0, "average": 0.986295, "min": 0.986295}, "location": {"width": 80, "top": 1346, "height": 28, "left": 945}, "words": "米"}, {"probability": {"variance": 0.000223, "average": 0.994528, "min": 0.913941}, "location": {"width": 828, "top": 1389, "height": 30, "left": 244}, "words": "健康志愿者接受CYP3A4诱导剂卡马西平,每天2次,每次100mg连用3天和每天"}, {"probability": {"variance": 8e-06, "average": 0.998378, "min": 0.986653}, "location": {"width": 641, "top": 1435, "height": 30, "left": 202}, "words": "2次,每次200mg连用17天,本品的全身暴露量下降大约72%"}, {"probability": {"variance": 1e-06, "average": 0.998859, "min": 0.997786}, "location": {"width": 49, "top": 1503, "height": 27, "left": 203}, "words": "清除"}, {"probability": {"variance": 1e-06, "average": 0.997973, "min": 0.997264}, "location": {"width": 20, "top": 1560, "height": 20, "left": 635}, "words": "24"}], "language": 3}